Effect of N-acetyl cysteine on controling clinical symtoms and inflammatory biomarkers in rhumatoid arthritis Patients

Evaluating the effects of oral N-acetyl cysteine as a Adjuvant therapy on controling clinical symtoms and serum level of inflammatory biomarkers including IL6,TNF-a, CRP and ESR in rhumatoid arthritis Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015071722965N2

Enrollment

Registered

2015-11-06

Start date

2015-01-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis, unspecified

Interventions

Intervention 1: Intervention group: Standard regimen plus NAC 600 mg twice daily for 12 months. Intervention 2: Control group: Standard regimen without NAC.

Prevention

Intervention group: Standard regimen plus NAC 600 mg twice daily for 12 months

Control group: Standard regimen without NAC

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with diagnosis of arthritis rhumatoid; Patients more than 18 years and less than 65 years; Patients with moderate to severe active disease Exclusion criteria: Patients with active infection; Patients with mild active disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IL-6,TNF-alfa. Timepoint: Baseline, after 12 months. Method of measurement: serum level.	—

Secondary

Measure	Time frame
Assesment of clinical symptoms. Timepoint: Baseline, after 12 months. Method of measurement: Disease Activity Score, version 28 questionnaire.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026